References

WHO-EORTC classification for cutaneous lymphomas

10.1182/blood-2004-09-3502 · 2005 · External reference

Revisions to the staging and classification of mycosis fungoides and sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC)

10.1182/blood-2007-03-055749 · 2007 · External reference

Unresolved reference

2026 · External reference

Health-related quality of life and economic implications of cutaneous T-cell lymphoma

10.1111/bjd.17941 · 2020 · External reference

Unresolved reference

2025 · External reference

Efficacy and safety of denileukin diftitox-cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma

10.1200/jco-24-01549 · 2025 · External reference

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma

10.3816/clm.2006.n.039 · 2006 · External reference

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

10.1002/cncr.21449 · 2005 · External reference

Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012

10.1200/jco.2011.39.8065 · 2012 · External reference

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

10.1016/s0190-9622(89)70049-9 · 1989 · External reference

Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma

10.1093/jnci/82.3.208 · 1990 · External reference

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/sezary syndrome

10.1182/blood-2002-09-2802 · 2003 · External reference

Pembrolizumab in relapsed and refractory mycosis fungoides and sézary syndrome: a multicenter phase II study

10.1200/jco.19.01056 · 2020 · External reference

Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins

10.1158/1078-0432.ccr-11-0556 · 2011 · External reference

Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

10.1016/s0140-6736(17)31266-7 · 2017 · External reference

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

10.1016/s1470-2045(18)30379-6 · 2018 · External reference

Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma

10.1158/1078-0432.ccr-16-2064 · 2017 · External reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

10.1200/jco.2010.28.9066 · 2010 · External reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

10.1200/jco.2006.10.2434 · 2007 · External reference

Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma

2001 · External reference

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory hodgkin’s lymphoma

10.1200/jco.2011.38.0410 · 2012 · External reference

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

10.1200/jco.2011.38.0402 · 2012 · External reference

Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with Variable CD30 expression level: a multi-institution collaborative project

10.1200/jco.2014.60.3969 · 2015 · External reference

Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma

10.1016/j.jdcr.2021.12.032 · 2022 · External reference

Brentuximab-induced splinter nail haemorrhages in a patient with sézary syndrome: a case report

10.1111/bcp.15247 · 2022 · External reference

Brentuximab vedotin-induced tumour lysis syndrome in mycosis fungoides: a case report

10.2340/actadv.v104.41982 · 2024 · External reference

New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia

10.1111/bjd.17533 · 2019 · External reference

Case report: brentuximab vedotin associated acute pancreatitis in a pediatric hodgkin lymphoma patient: case report and literature review

10.3389/pore.2022.1610445 · 2022 · External reference

Brentuximab-induced pneumonitis and organizing pneumonia: a case report with literiture review

10.1097/ms9.0000000000001878 · 2024 · External reference

Hypertriglyceridemia induced pancreatitis due to brentuximab therapy: first case report

10.7759/cureus.5138 · 2019 · External reference

Progressive multifocal leukoencephalopathy during the treatment for mycosis fungoides

10.11406/rinketsu.63.206 · 2022 · External reference

Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin

10.1136/bcr-2022-251867 · 2024 · External reference

Mogamulizumab-kpkc: a novel therapy for the treatment of cutaneous T-cell lymphoma

10.6004/jadpro.2019.10.8.10 · 2019 · External reference

Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or sézary syndrome

10.1001/jamadermatol.2021.0877 · 2021 · External reference

Mogamulizumab-associated rash: a challenging case report and literature review

10.1111/ajd.14022 · 2023 · External reference

Mogamulizumab-associated rash—case series and review of the literature

10.1111/ddg.15432 · 2024 · External reference

Acneiform type of mogamulizumab-associated rash

10.1111/ddg.15816 · 2025 · External reference

Mogamulizumab-induced mucocutaneous lichenoid reaction: a case report and short review

10.2340/00015555-3527 · 2020 · External reference

Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with sézary syndrome

10.1016/j.jdcr.2020.12.035 · 2021 · External reference

Alopecia areata-like presentations with mogamulizumab therapy

10.1016/j.jdcr.2023.08.044 · 2023 · External reference

Mogamulizumab-associated rash: cutaneous T-cell lymphoma in complete remission

10.1007/s00105-024-05349-0 · 2024 · External reference

Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/sézary syndrome; a single-center experience

10.1016/j.jaad.2023.05.082 · 2023 · External reference

Mogamulizumab-associated myositis with and without myasthenia Gravis and/or myocarditis in patients with T-cell lymphoma

10.1093/oncolo/oyad155 · 2023 · External reference

Alopecia areata after mogamulizumab treatment

10.1016/j.jdcr.2021.10.034 · 2022 · External reference

Scarring alopecia developing after mogamulizumab-associated rash

10.1684/ejd.2021.4179 · 2021 · External reference

Mogamulizumab-induced vitiligo in patients with sézary syndrome: three cases

10.1684/ejd.2021.4002 · 2021 · External reference

Two cases of generalized eruptive lentiginosis in cutaneous T-cell lymphoma following mogamulizumab treatment

10.1111/ijd.16102 · 2022 · External reference

Mogamulizumab associated crusted scabies: a rare diagnostic confounder

10.23736/s2784-8671.24.07953-2 · 2024 · External reference

Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management

10.1016/j.jdcr.2024.09.021 · 2024 · External reference

Mogamulizumab for sézary syndrome: long-term remission with associated autoimmune haemolytic anaemia

10.1684/ejd.2024.4744 · 2024 · External reference

Mogamulizumab-associated lymphadenopathy masquerading as lymphoma progression

10.1016/j.jdcr.2026.01.046 · 2026 · External reference

BK polyomavirus-associated progressive multifocal leukoencephalopathy following mogamulizumab therapy for erythrodermic mycosis fungoides

10.3389/fcimb.2026.1733473 · 2026 · External reference

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

10.1200/jco.2010.29.9024 · 2011 · External reference

Efficacy, quality of life, and safety of methotrexate versus interferon in head-to-head treatment in advanced stages of mycosis fungoides and sezary syndrome. Prospective trial (NCT02323659)

10.5114/ada.2021.106206 · 2021 · External reference

Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients

10.1016/s0190-9622(96)80062-4 · 1996 · External reference

Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients

10.1016/s0190-9622(03)01591-3 · 2003 · External reference

Cutaneous methotrexate-related epstein–barr virus-positive diffuse large B-cell lymphoma in a patient with granulomatous cutaneous T-cell lymphoma: a case report and literature review

10.2147/ccid.s419534 · 2023 · External reference

Methotrexate-associated B-cell lymphoproliferative disease in a patient with cutaneous T-cell lymphoma

10.1001/jamadermatol.2017.6062 · 2018 · External reference

Cutaneous cryptococcosis in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate

10.1093/clinids/17.4.776 · 1993 · External reference

Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides

10.2147/tcrm.s1155 · 2008 · External reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

10.1200/jco.2008.21.6150 · 2009 · External reference

Romidepsin-induced neutrophilic urticaria

10.1016/j.jdcr.2016.05.013 · 2016 · External reference

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma

10.3816/clm.2009.n.082 · 2009 · External reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

10.1182/blood-2006-06-025999 · 2007 · External reference

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

10.1200/jco.2001.19.9.2456 · 2001 · External reference

Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma

10.1016/j.medcli.2015.07.017 · 2016 · External reference

Reversible pituitary insufficiency due to bexarotene therapy in a patient with mycosis fungoides

10.1007/s11102-013-0523-z · 2014 · External reference

Acute hyperkeratotic and desquamative reaction in a patient with sézary syndrome treated with bexarotene

10.1111/j.1468-3083.2007.02341.x · 2008 · External reference

Development of hodgkin’s lymphoma under bexarotene treatment for sézary syndrome and review of the literature

2010 · External reference

Bexarotene treatment of late-stage mycosis fungoides and sézary syndrome: development of extracutaneous lymphoma in 6 patients

10.1016/j.jaad.2005.02.055 · 2005 · External reference

Denileukin diftitox: a concise clinical review

10.1586/14737140.5.1.33 · 2005 · External reference

Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis

10.1002/ajh.21180 · 2008 · External reference

Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine

10.1007/s00277-014-2121-1 · 2014 · External reference

Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases

10.1111/j.1365-2133.2009.09230.x · 2009 · External reference

Linear immunoglobulin a bullous dermatosis induced by gemcitabine

10.1345/aph.10268 · 2001 · External reference

Stevens–Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine

10.1097/00001813-200309000-00012 · 2003 · External reference

Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma

10.1093/bjd/ljad311 · 2024 · External reference

Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or sézary syndrome

10.1001/archderm.144.6.727 · 2008 · External reference

Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas

10.1111/ced.15224 · 2022 · External reference

Preventing hand-foot syndrome in patients with cancer: a systematic review and network meta-analysis

10.1001/jamadermatol.2026.0042 · 2026 · External reference

Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides

10.1111/j.1600-0609.2005.00497.x · 2005 · External reference

Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma

10.1093/jnci/82.3.203 · 1990 · External reference

Interferon α-induced lupus-like reaction in a mycosis fungoides patient: a case report

10.5414/cp204003 · 2022 · External reference

Low-dose intermittent alemtuzumab in the treatment of sézary syndrome: clinical and immunologic findings in 14 patients

10.3324/haematol.11127 · 2007 · External reference

Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab)

10.1111/cup.12800 · 2016 · External reference

Treatment of patients with advanced mycosis fungoides and sézary syndrome with alemtuzumab

10.1034/j.1600-0609.2003.00143.x · 2003 · External reference

Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian oncology summit 2009

10.1016/s1470-2045(09)70265-7 · 2009 · External reference

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

10.1182/blood-2008-02-138800 · 2008 · External reference

Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas

10.1111/bjd.12690 · 2014 · External reference

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie comprehensive cancer center

10.3109/10428190903216770 · 2009 · External reference

Transformation of sézary syndrome into CD30 + anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity

10.1097/dad.0000000000000156 · 2015 · External reference

Differential expression of programmed death-1 (PD-1) in sézary syndrome and mycosis fungoides

10.1001/archdermatol.2012.2089 · 2012 · External reference

Pembrolizumab in relapsed or refractory mycosis fungoides or sézary syndrome

10.1001/jamadermatol.2025.0251 · 2025 · External reference

Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment

10.1172/jci.insight.164793 · 2023 · External reference

Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma

2005 · External reference

Mycosis fungoides, sézary syndrome, and cutaneous B-cell lymphomas: 2025 update on diagnosis, risk-stratification, and management

10.1002/ajh.27735 · 2025 · External reference